Last reviewed · How we verify

Pritor

DongKoo Bio & Pharma · Phase 1 active Small molecule Under review

Pritor is a Small molecule drug developed by DongKoo Bio & Pharma. It is currently in Phase 1 development for Cerebrovascular accident, Disorder due to type 2 diabetes mellitus, History of myocardial infarction due to atherothrombotic coronary artery disease.

Telmisartan is a medication used to treat high blood pressure and heart failure. It works as a type-1 angiotensin II receptor antagonist, a small molecule that blocks the action of angiotensin II on its receptor.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePritor
SponsorDongKoo Bio & Pharma
TargetATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor
ModalitySmall molecule
Therapeutic areaMetabolic
PhasePhase 1

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pritor

What is Pritor?

Pritor is a Small molecule drug developed by DongKoo Bio & Pharma, indicated for Cerebrovascular accident, Disorder due to type 2 diabetes mellitus, History of myocardial infarction due to atherothrombotic coronary artery disease.

What is Pritor used for?

Pritor is indicated for Cerebrovascular accident, Disorder due to type 2 diabetes mellitus, History of myocardial infarction due to atherothrombotic coronary artery disease, Hypertensive disorder, Myocardial Infarction Prevention.

Who makes Pritor?

Pritor is developed by DongKoo Bio & Pharma (see full DongKoo Bio & Pharma pipeline at /company/dongkoo-bio-pharma).

What development phase is Pritor in?

Pritor is in Phase 1.

What does Pritor target?

Pritor targets ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing